ALLOUCHERY, Marion; TOMOWIAK, Cécile; SINGIER, Allison; PUYADE, Mathieu; DARI, Loubna; PAMBRUN, Elodie; PARIENTE, Antoine; BEZIN, Julien; PÉRAULT-POCHAT, Marie-Christine; SALVO, Francesco

doi:10.1111/bjh.18995

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

ALLOUCHERY, Marion

Bordeaux population health [BPH]

TOMOWIAK, Cécile

SINGIER, Allison

Bordeaux population health [BPH]

Langue

Article de revue

Ce document a été publié dans

British Journal of Haematology. 2023-10-01, vol. 203, n° 2, p. 311-318

Résumé en anglais

Data regarding the safety of co-administration of ibrutinib with anticoagulants in real-life settings are scarce. Using a nationwide database, we conducted a nested case-control study in a cohort of new users of ibrutinib to assess the risk of clinically relevant bleeding (CRB) associated with anticoagulation. Cases were patients with a diagnosis of CRB, defined as hospitalization with a diagnosis of bleeding. The date of CRB constituted the index date. Up to four controls were matched on sex, age at index date and duration of follow-up. The risk of CRB associated with anticoagulation in patients receiving ibrutinib was estimated using conditional logistic regression models, providing odds ratios (OR) adjusted for risk factors of bleeding. Among 614 cases and 2407 matched controls, the risk of CRB was significantly higher in patients receiving both ibrutinib and anticoagulants (adjusted OR [aOR] 2.54, confidence interval [CI] 95% [1.94; 3.32]). When considering anticoagulant class, aOR was 1.99 (CI 95% [1.19; 3.33]) for VKA, 2.48 (CI 95% [1.76; 3.47]) for direct oral anticoagulants and 3.40 (CI 95% [2.01; 5.75]) for parenteral anticoagulants. In conclusion, this study found a 2.5-fold increased risk of CRB in patients receiving both ibrutinib and anticoagulants in real-life settings, and similar aOR among oral anticoagulants.< Réduire

Mots clés en anglais

Humans

Anticoagulants

Case-Control Studies

Hemorrhage

Piperidines

Administration

Oral

Atrial Fibrillation

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Bleeding risk with concurrent use of anticoagulants and ibrutinib: A population-based nested case-control study

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche